

PTO/SB/08A (04-03)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	10/626,389
Filing Date	07/24/2003
First Named Inventor	Hayashi, T. et al
Art Unit	1615
Examiner Name	/Humera Sheikh/
Attorney Docket Number	11/379

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ²
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
HS		WO 02/28373	04/11/2002	Boehringer Ingelheim		
				International GmbH		
HS		WO 02/20018	03/14/2002	Boehringer Ingelheim		
				International GmbH		
HS		WO 01/51038	07/19/2001	Laboratorios Phoenix		

Examiner Signature	/Humera Sheikh/	Date Considered	10/01/2006
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinda Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/626,389		
		Filing Date	07/24/2003		
		First Named Inventor	Hayashi, T. et al		
		Art Unit	1615		
		Examiner Name	/Humera Sheikh/		
Sheet	2	of	2	Attorney Docket Number	1/1379

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
HS		New antitussive medicinal compositions-comprises ketotifen, epinastine and methyl-ephedrine, methoxy-phenamine; tri:meto-quinol, theophylline, aminophylline, di:prophylline and/or proxy-phylline, Derwent Abstract XP 002225255 of JP 11071281	
HS		Internal Medicine for rhinitis-comprises phenyl-propanol-amine-, phenyl-ephedrine, methyl-ephedrine or methoxy-phenamine and ketotife fumarate and/or epinastine hydrochloride, Derwent Abstract XP 002225257 of JP10045576	
HS		Pharmaceutical Composition for common cold having improved after-taste-contains Stevia and e.g. codeine phosphate, lysozyme chloride, clemastine fumarate and Ibudilast, Derwent Abstract XP002225256 of JP9052849	
HS		Patent Abstracts of Japan vol. 2003, no. 07, July 3, 2002 and JP 2003 089638 A (Taisho Pharmaceutical Co. Ltd), March 28, 2003 abstract	

Examiner Signature	/Humera Sheikh/	Date Considered	10/01/2006
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.